Drugs / IVT GBS-06
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06611371 | Nov 2024 → Aug 2025 overdue | group B streptococcal infection | Inventprise Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-23 | Inventprise Inc. | Results Inventprise Announces Positive Interim Results from the Phase 1/2 clinical study for Hexavalent Group B Streptococcal Vaccine Candidate (IVT GBS-06) inventprise.com ↗
All vaccine dose levels were well tolerated, with no related serious adverse events reported. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-02-23 | Inventprise Inc. | Inventprise Announces Positive Interim Results from the Phase 1/2 clinical study for Hexavalent Group B Streptococcal Vaccine Candidate (IVT GBS-06) inventprise.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVT GBS-06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06611371 ↗ |
| Modality | Vaccine | “Hexavalent Group B Streptococcus polysaccharide conjugate vaccine” NCT06611371 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT06611371 ↗ |